UAMY: Buy Rating Clashes with Execution Reality – Volumes Up, Margins Down, Government Ramp Unproven

What happened

UAMY's Q2 2026 volume rose 26% year-over-year to 428,425 pounds of antimony, but realized prices plunged 52% to $13.70/lb, compressing gross margin from 27% to 7% and driving a 16% first-half revenue decline. A Seeking Alpha article rates UAMY a Buy with a $10-11 target, arguing the market overreacts to weak pricing and trailing revenue while a $245 million government contract ramps up. However, the DeepValue master report rates UAMY a Potential Sell, citing management's FY2026 revenue guidance cut to $60-$75 million from $125 million, first-half operating cash outflow of $20.7 million, and inventory build to $21.6 million without commensurate monetization. The core dispute centers on the Defense Logistics Agency contract: the article sees upside as deliveries accelerate, while the master report notes that revenue recognition depends on shipment acceptance, and only $2.6 million of June shipments were deferred to Q3 pending formal acceptance. Until Q3 results confirm recognized DLA revenue, gross margin recovery, and inventory drawdown, the master report's cautious stance appears more grounded than the article's optimistic catch-up call.

Implication

Investors should treat the Seeking Alpha Buy rating with skepticism because it ignores the sharp margin compression and relies on unproven contract conversion. The next quarterly report is pivotal: UAMY must recognize the deferred $2.6 million DLA shipment and show progress toward the guided $9-$10 million in Q3 government sales. If Q3 results miss those benchmarks or if inventory rises further without corresponding revenue, the bear case strengthens and the stock could revisit the $4.00 bear scenario. Conversely, a clean quarter with accepted shipments, margin recovery above 15%, and inventory decline would validate the bull case and could push the stock toward $6.75. Given the current price near $5.34 and the asymmetric risk, we recommend reducing positions above $6.50 and only considering accumulation below $3.75 pending execution evidence.

Thesis delta

The article reiterates the bull case—volume growth and government catalyst—but does not address the critical near-term benchmarks: recognized DLA revenue, gross margin recovery, and inventory drawdown. Until those metrics improve, the thesis remains unchanged: risk-reward is unfavorable at current prices, and we would trim above $6.50.